Physician profile
Rodrigo Lema
NPI 1336194851
$2,599.05
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $187 · 2021: $133 · 2022: $226 · 2023: $298 · 2024: $352 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $920.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $522.08 | 2019-2024 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.81 | 2019-2025 | Jascayd, Ofev |
| Philips North America LLC | $134.37 | 2019-2024 | (O58) Sleep Respiratory Care Und |
| United Therapeutics Corporation | $88.62 | 2023-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $87.04 | 2019 | |
| Resmed Corp | $86.00 | 2019 | |
| Insmed, INC. | $79.72 | 2019-2025 | Arikayce |
| Baxter Healthcare | $74.18 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $71.01 | 2019-2025 | Smartvest |
| Genzyme Corporation | $59.23 | 2021-2025 | |
| Lilly USA, LLC | $40.68 | 2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $40.67 | 2024 | Inspire |
| Inogen, INC. | $40.24 | 2023-2025 | Inogen |
| Sunovion Pharmaceuticals INC. | $36.34 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $23.67 | 2021 | |
| Grifols USA, LLC | $22.44 | 2024 | Prolastin-C Liquid |
| Verona Pharma, INC. | $22.33 | 2025 | Ohtuvayre |
| Phadia US INC. | $21.53 | 2024 | Immunocap |
| Mylan Specialty L.P. | $19.18 | 2023 | Yupelri |
| Pfizer INC. | $16.08 | 2019 | |
| Merck Sharp & Dohme LLC | $15.24 | 2024 | Keytruda |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Lema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.